Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET TrialDhivya R Sudhan, Luis J Schwarz, Angel Guerrero-Zotano, et al.
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2012
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer modelsRoberta Rosa, Roberta Marciano, Umberto Malapelle, et al.
British Journal of Cancer|April 26, 2017
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancersConcetta Di Mauro, Roberta Rosa, Valentina D'Amato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2021
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast CancerAlberto Servetto, Rahul Kollipara, Luigi Formisano, et al.
Therapeutic Advances in Medical Oncology|October 16, 2020
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedulesFrancesca Foschini, Fabiana Napolitano, Alberto Servetto, et al.
European Urology Oncology|July 11, 2025
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysisFabiano Flauto, Giuseppe Neola, Carmine Caso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2018
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast CancerSarah Croessmann, Luigi Formisano, Lisa N Kinch, et al.
Nature Communications|October 31, 2020
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancerKyung-Min Lee, Angel L Guerrero-Zotano, Alberto Servetto, et al.
NPJ Breast Cancer|September 26, 2019
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancerMellissa J Nixon, Luigi Formisano, Ingrid A Mayer, et al.
Pageof 18